Open Beta
MetriLume

US marketsCORT

SEC-sourced researchBeta

CORT

CORCEPT THERAPEUTICS INC

Company comparison ↗

Data passport

CIK
0001088856
Exchange
Nasdaq
Business activity
— · SIC 2834
Financial inputs
6/6
Filing date
Oct 5, 2026
SEC registry record
Operating company

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 482,375,000.0000 USD; December 2024: 675,040,000.0000 USD; December 2025: 761,407,000.0000 USD761.4M USD0 USD0December 2023December 2024December 2025
CORT · Exact amounts and source periods · USD
Period endRevenueFiling date
December 2023482,375,000.0000Feb 24, 2026
December 2024675,040,000.0000Feb 24, 2026
December 2025761,407,000.0000Feb 24, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 2025761,407,000.000099,652,000.0000141,996,000.0000836,651,000.0000188,846,000.0000Feb 24, 2026
December 2024675,040,000.0000141,209,000.0000198,295,000.0000840,553,000.0000160,964,000.0000Feb 24, 2026
December 2023482,375,000.0000106,140,000.0000126,681,000.0000——Feb 24, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$761.41MDecember 2025Feb 24, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$675.04MDecember 2024Feb 24, 202610-K
Net incomeNetIncomeLoss$99.65MDecember 2025Feb 24, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities$142MDecember 2025Feb 24, 202610-K
Total assetsAssets$836.65MDecember 2025Feb 24, 202610-K
Total liabilitiesLiabilities$188.85MDecember 2025Feb 24, 202610-K

New filings

Explore methodology ↗